Drug Profile
Research programme: chronic obstructive pulmonary disease therapeutics - Medivir
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Medivir AB
- Class
- Mechanism of Action Matrix metalloproteinase 12 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in Sweden
- 28 Nov 2007 Preclinical trials in Chronic obstructive pulmonary disease in Sweden (unspecified route)